Hemophilia A is a X-linked disorder characterized by less than 1% of blood clotting Factor VIII in the blood and is usually managed by hemostatic products to stop or prevent bleeding. While an adeno-associated virus vector has been approved to treat hemophilia A, this gene therapy is not approved for children and Factor VIII expression declines after 6 to 12…